EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort

Ullas Batra iD, Kumar Prabhash iD, Vanita Noronha iD, Ramakant Deshpande, Sachin Khurana iD, Gull Mohammad Bhat, Rajesh Mistry, Vivek Agarwala iD, Sajjan Rajpurohit, Bhavesh Poladia, Mansi Sharma iD, Saquib Zaffar Banday

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00353 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Ullas Batra und 11 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, Rohini, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The spectrum of EGFR is inadequately researched in patients with early-stage non–small cell lung cancer (NSCLC) in India. EARLY-epidermal growth factor receptor (EGFR) India (ClinicalTrials.gov identifier: NCT04742192 ), as part of a noninterventional, real-world global study, evaluated the prevalence of EGFR mutations in early-stage NSCLC in India. METHODS Prospective data from adult patients with surgically resected stage IA to IIIB (American Joint Committee on Cancer eighth edition) NSCLC between March 2021 and October 2022 were analyzed. In addition to descriptive statistics, Fisher's exact test with Monte Carlo was used to determine the association between EGFR mutations and clinicodemographic parameters. RESULTS Of 74 patients (median age, 57.0 [range, 33.0-77.0] years) enrolled from eight centers in India, 73.0% (54 of 74) were males, 56.1% (37 of 66) were nonsmokers, and 95.9% (71 of 74) had adenocarcinoma. The EGFR mutation prevalence was 26.0% (19 of 73), of which Exon-19 deletions were the predominant subtype (13, 68.4%) followed by Exon 21-L858R (4, 21.1%), Exon 20-T790M (1, 5.3%), and compound (1, 5.3%) mutations. Nearly half (48.6%, 36 of 74) of the patients underwent only surgical resection. The remaining 51.4% (38 of 74) of the patients were prescribed neoadjuvant (n = 12; 16.2%) and adjuvant (n = 31; 41.9%) systemic therapies, and one patient (1.4%) received radiotherapy along with systemic therapy. In 60 patients with stage IB to IIIB NSCLC, systemic therapies, mainly platinum-based chemotherapy, were prescribed in 36 (60.0%). Only 8.1% (6 of 74) of the patients were prescribed EGFR-tyrosine kinase inhibitor (TKI), of which two received neoadjuvant and four were planned for adjuvant EGFR-TKI. Two (2.7%) patients were prescribed adjuvant immunotherapy. The univariate analysis showed higher odds of EGFR mutation for females (odds ratio, 3.96; P = .017). CONCLUSION EARLY-EGFR India results showed the prevalence of EGFR mutation to be 26%. The study emphasized the pressing need for up-front biomarker testing at diagnosis to ensure optimal and timely personalized treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMutationNeoplasm StagingAdultAgedFemaleHumansMaleMiddle AgedIndiaPrevalenceProspective Studies

Substanzen

EGFR protein, humanErbB Receptors

Autor:innen und Institutionen

  • Thoracic Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, Rohini, India.
  • Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Asian Cancer Institute, Mumbai, India.
  • Department of Medical Oncology, AIIMS New Delhi, Delhi, India.
  • Medical Oncology, National Institute for Medical Science and Research, Jaipur, India.
  • Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.

ORCID-Profile: Ullas Batra, Kumar Prabhash, Vanita Noronha, Sachin Khurana, Vivek Agarwala, Mansi Sharma

Zitieren

APA

Batra, U., Prabhash, K., Noronha, V., Deshpande, R., Khurana, S., Bhat, G. M., Mistry, R., Agarwala, V., Rajpurohit, S., Poladia, B., Sharma, M., & Banday, S. Z. (2025). Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort. JCO Global Oncology. https://doi.org/10.1200/go-24-00353

Vancouver

Batra U, Prabhash K, Noronha V, Deshpande R, Khurana S, Bhat GM, et al. Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort. JCO Global Oncology. 2025. doi:10.1200/go-24-00353

BibTeX
@article{Batra2025,
  author = {Batra, Ullas and Prabhash, Kumar and Noronha, Vanita and Deshpande, Ramakant and Khurana, Sachin and Bhat, Gull Mohammad and Mistry, Rajesh and Agarwala, Vivek and Rajpurohit, Sajjan and Poladia, Bhavesh and Sharma, Mansi and Banday, Saquib Zaffar},
  title = {Prevalence of EGFR Mutations in Patients With Resected Stage I to III Nonsquamous Non–Small Cell Lung Cancer: Results of India Cohort},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00353}
}
Kostenlos starten →